Blurbs

Analysts Offer Insights on Healthcare Companies: Aileron Therapeutics (ALRN), NRX Pharmaceuticals (NRXP) and Cybin (CYBN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aileron Therapeutics (ALRNResearch Report), NRX Pharmaceuticals (NRXPResearch Report) and Cybin (CYBNResearch Report) with bullish sentiments.

Aileron Therapeutics (ALRN)

H.C. Wainwright analyst Edward White maintained a Buy rating on Aileron Therapeutics today and set a price target of $1.00. The company’s shares closed last Wednesday at $0.30, close to its 52-week low of $0.26.

According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -27.5% and a 23.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

Aileron Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $1.00.

See today’s best-performing stocks on TipRanks >>

NRX Pharmaceuticals (NRXP)

NRX Pharmaceuticals received a Buy rating and a $2.00 price target from H.C. Wainwright analyst Vernon Bernardino today. The company’s shares closed last Wednesday at $0.57, close to its 52-week low of $0.49.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 21.3% and a 33.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Aridis Pharmaceuticals, and Citius Pharmaceuticals.

Currently, the analyst consensus on NRX Pharmaceuticals is a Moderate Buy with an average price target of $2.00.

Cybin (CYBN)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Cybin today and set a price target of $10.00. The company’s shares closed last Wednesday at $0.56, close to its 52-week low of $0.39.

According to TipRanks.com, Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.6% and a 30.6% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on Cybin is a Strong Buy with an average price target of $8.35, a 1460.5% upside from current levels. In a report issued on June 23, Canaccord Genuity also maintained a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos